| ［1］World Health Organization. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva: World Health Orgnization,2011.［2］Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that leads to rifampin resistance. J Mol Biol，1988，202（1）: 45-58.［3］全国结核病流行病学抽样调查技术指导组，全国结核病流行病学抽样调查办公室.2000年全国结核病流行病学抽样调查报告. 中国防痨杂志，2002，24（2）：65-108．［4］全国第五次结核病流行病学抽样调查技术指导组，全国第五次结核病流行病学抽样调查办公室.2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志，2012，34（8）：485-508．［5］中国防痨协会.结核病诊断细菌学检验规程．中国防痨杂志, 1996,18（1）:28-31．［6］Aslan G, Tezcan S, Serin MS, et al. Genotypic analysis of isoniazid and rifampin resistance in drug-resistant clinical Mycobacterium tuberculosis complex isolates in southern Turkey. Jpn J Infect Dis，2008，61(4):255-260.［7］Lipin MY, Stepanshina VN, Shemyakin IG, et al. Association of specific mutations in katG, rpoB, rpsL and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia.Clin Microbiol Infect，2007，13(6):620-626.［8］Nikolayevskyy VV, Brown TJ, Bazhora YI, et al. Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern Ukraine. Clin Microbiol Infect，2007，13(2):129-138.［9］Jenkins C, Bacon J, Allnutt J, et al. Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH. J Antimicrob Chemother，2009，63(6):1118-1120.［10］Zaczek A, Brzostek A, Augustynowicz-Kopec E, et al. Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol，2009, 9:10.［11］Shiohira CM, Yamane N. Determination of genetic mutations in rpoB of the isolates of Mycobacterium tuberculosis complex those susceptibilities to rifampicin were interpreted as indeterminate by Broth MIC MTB. Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi，2006，17(2):107-114.［12］Ohno H, Koga H, Ogawa K, et al.Genetic evaluation for rifampicin-susceptibility of Mycobacterium tuberculosis.Kansenshogaku Zasshi，1997，71(4):323-328.［13］Isakova ZhT.Distribution of mutations in the rpoB, katG, inhA, ahpC gene of rifampicin and isoniazid resistant M. tuberculosis strains isolated in Kyrgyz Republic. Mol Gen Mikrobiol Virusol，2008，(4):36-38.［14］Guo JH, Xiang WL, Zhao QR, et al.Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates from Sichuan Province in China. Jpn J Infect Dis，2008，61(4):264-268.［15］Wu X, Zhang J, Chao L, et al.Identification of rifampin-resistant genotypes in Mycobacterium tuberculosis by PCR-reverse dot blot hybridization. Mol Biotechnol，2009，41(1):1-7.［16］刘敬华，张丽水，刘志广，等.结核分枝杆菌利福平耐药基因rpoB突变特征初步分析.中华流行病学杂志，2006，27(11):973-976.［17］Isfahani BN, Tavakoli A, Salehi M, et al.Detection of rifampin resistance patterns in Mycobacterium tuberculosis strains isolated in Iran by polymerase chain reaction-singlestrand conformation polymorphism and direct sequencing methods. Mem Inst Oswaldo Cruz，2006，101(6):597-602.［18］Jiang X, Zhang W, Zhang Y, et al.Assessment of efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription PCR. Microb Drug Resist，2008，14(1):7-11.［19］Safi H, Sayers B, Hazbón MH, et al.Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother，2008，52(6):2027-2034.［20］Shi R, Zhang J, Otomo K, et al.Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China. Antimicrob Agents Chemother，2007，51(12):4515-4517.［21］Heysell SK, Moore JL, Keller SJ, et al. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis，2010，16(10):1546-1553.［22］Weiner M, Peloquin C, Burman W, et al.Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother， 2010，54(10):4192-4200. |
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
